Iterum Therapeutics plc (ITRM) |
| 0.03 -0.004 (-10.98%) 03-31 16:00 |
| Open: | 0.0415 |
| High: | 0.047 |
| Low: | 0.0283 |
| Volume: | 49,297,937 |
| Market Cap: | 2(M) |
| PE Ratio: | -0.04 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.09 |
| Resistance 1: | 0.08 |
| Pivot price: | 0.05 |
| Support 1: | 0.03 |
| Support 2: | 0.00 |
| 52w High: | 1.42 |
| 52w Low: | 0.0271 |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Financials
| EPS | -19320000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -1.00 |
| Return on Assets (ttm) | 982.3 |
| Return on Equity (ttm) | -53.3 |
Company news
Wed, 01 Apr 2026
Breakeven On The Horizon For Iterum Therapeutics plc (NASDAQ:ITRM) - simplywall.st
Wed, 01 Apr 2026
Iterum Therapeutics plc (NASDAQ:ITRM): Are Analysts Optimistic? - Yahoo Finance
Tue, 31 Mar 2026
Iterum Therapeutics Received Notice of Delisting - TradingView
Tue, 31 Mar 2026
Iterum Therapeutics to be delisted from Nasdaq as winding up process advances - Investing.com
Mon, 30 Mar 2026
What's Going On With Iterum Therapeutics Stock Monday? - Benzinga
Fri, 27 Mar 2026
Iterum Therapeutics (NASDAQ: ITRM) seeks court-backed wind up - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
